agilon health

Yahoo Finance • last month

Agilon Health Inc (AGL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges

Revenue: $1.52 billion for Q4 2024, $6.06 billion for the full year, a 44% increase year-over-year. Medical Margin: $1 million for Q4 2024, $205 million for the full year. Adjusted EBITDA: Minus $84 million for Q4 2024, minus $154 million... Full story

Yahoo Finance • last month

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of agilon health, inc. (NYSE: AGL) and Encourages Long-Term Investors to Contact the Firm

PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating agilon health, inc. (NYSE: AGL) on behalf of the company’s long-term shareholders. Click here for additional information: https://kaskel... Full story

Yahoo Finance • 2 months ago

Why Agilon Health Inc (AGL) Is Skyrocketing So Far In 2025

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Agilon Health Inc (NYSE:AGL) stands against the other healthcare stocks. The healthcar... Full story

Yahoo Finance • last year

15 Best Growth Stocks to Buy Under $25

In this article, we present 15 best growth stocks under $25. If you want to skip our discussion on the performance of growth stocks, head directly to 5 Best Growth Stocks Under $25. The markets have rallied for the better part of the year... Full story

Yahoo Finance • 2 years ago

15 Most Promising Mid-Cap Stocks According to Analysts

In this article, we will take a look at the 15 most promising mid-cap stocks according to analysts. To see more such companies, go directly to 5 Most Promising Mid-Cap Stocks According to Analysts. While the majority only focuses on major... Full story

Yahoo Finance • 3 years ago

Angle PLC Announces Identifying Therapeutic Targets in TNBC Patients

PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple actionable targets Both tumour and CTC sam... Full story